Vimarsana
Biggest News Aggregation in the World

Page 4 - Gravis Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gravis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gravis Foundation Today - Breaking & Trending Today

FDA Approves Rozanolixizumab-noli for Generalized Myasthenia Gravis - Vimarsana News

FDA Approves Rozanolixizumab-noli for Generalized Myasthenia Gravis

The treatment is the first approved by the FDA to treat the 2 most common subtypes of generalized myasthenia gravis.

Source: ajmc.com
Myasthenia Gravis Foundation of America (MGFA) Announces Official Start of MG Awareness Month Around the World - Vimarsana News

Myasthenia Gravis Foundation of America (MGFA) Announces Official Start of MG Awareness Month Around the World

/PRNewswire/ -- The MG Community around the world is turning Awareness into Action in June to educate everyone about the challenges of the rare neuromuscular...

Myasthenia Gravis Foundation of America (MGFA) Announces Alliance with Patients Rising to Offer MG Patient Advocacy and Support Services - Vimarsana News

Myasthenia Gravis Foundation of America (MGFA) Announces Alliance with Patients Rising to Offer MG Patient Advocacy and Support Services

/PRNewswire/ -- Two patient-centric advocacy organizations have created an alliance to help patients with chronic disease navigate the health care system....

Myasthenia Gravis Foundation of America (MGFA) Re-launches the MGFA Global MG Patient Registry with Partner Alira Health - Vimarsana News

Myasthenia Gravis Foundation of America (MGFA) Re-launches the MGFA Global MG Patient Registry with Partner Alira Health

/PRNewswire/ -- The Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization solely dedicated to the myasthenia...

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review - Vimarsana News

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized...